A new scheme is getting off the ground this week under which the UK government will make upfront payments to pharmaceutical companies for access to new antibiotics for serious infections such as sepsis, bloodstream infections and hospital-acquired pneumonia, in an effort to stem the rise of antimicrobial resistance (AMR).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?